Synergy between RU 28965 (roxithromycin) and human neutrophils for bactericidal activity in vitro.
The in vitro effects of RU 28965 (roxithromycin), a new semisynthetic macrolide, on human neutrophil activity were compared with those of erythromycin. RU 28965, at a concentration as low as 0.1 microgram/ml, significantly enhanced the phagocytosis and killing of Staphylococcus aureus by neutrophils. Erythromycin displayed a less stimulating effect in a dose-dependent manner. Phagocytosis of Klebsiella pneumoniae was also increased after incubation of neutrophils with RU 28965, but killing was not altered. Neutrophil chemotaxis, myeloperoxidase activity, and O2 consumption were unchanged in the presence of RU 28965.
D001770:Blood Bactericidal Activity / Q000187:drug effects*; D002633:Chemotaxis / Q000187:drug effects; D003486:Cyanides / Q000494:pharmacology; D004917:Erythromycin / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007933:Leucomycins / Q000494:pharmacology*; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects; D009195:Peroxidase / Q000378:metabolism; D010587:Phagocytosis / Q000187:drug effects
D003486:Cyanides; D007933:Leucomycins; D004917:Erythromycin; D009195:Peroxidase